# Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

> **NCT05702268** · PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 75 (estimated)

## Conditions studied

- Moderate to Severe Atopic Dermatitis

## Interventions

- **DRUG:** ICP-332
- **DRUG:** ICP-332 Placebo

## Key facts

- **NCT ID:** NCT05702268
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-18
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2023-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05702268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05702268, "Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05702268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*